CUR Share Price

Open 1.24 Change Price %
High 1.26 1 Day -0.03 -2.42
Low 1.20 1 Week 0.00 0.00
Close 1.21 1 Month -0.14 -10.37
Volume 147860 1 Year 0.93 332.14
52 Week High 6.60
52 Week Low 0.23
CUR Important Levels
Resistance 2 1.27
Resistance 1 1.24
Pivot 1.22
Support 1 1.18
Support 2 1.15
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
NGD 3.29 -6.80%
NGD 3.29 -6.80%
RBY 0.03 -70.00%
LODE 0.12 -7.69%
PBTH 8.23 0.37%
GGR 0.02 100.00%
VTG 0.05 -16.67%
More..
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
MBA 0.20 25.00%
MBA 0.20 25.00%
MBA 0.20 25.00%
IG 7.68 22.49%
IG 7.68 22.49%
More..
AMEX USA Top Losers Stocks
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
QBC 0.20 -33.33%
LBY 6.84 -25.33%
ATL 0.06 -25.00%
ATL 0.06 -25.00%
SNT 0.12 -20.00%
INV 0.14 -17.65%
More..

Neuralstem, Inc. (AMEX: CUR)

CUR Technical Analysis 4
As on 31st Oct 2017 CUR Share Price closed @ 1.21 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.16 & Sell for SHORT-TERM with Stoploss of 1.26 we also expect STOCK to react on Following IMPORTANT LEVELS.
CUR Target for December
1st Target up-side 1.43
2nd Target up-side 1.59
3rd Target up-side 1.75
1st Target down-side 0.99
2nd Target down-side 0.83
3rd Target down-side 0.67
CUR Other Details
Segment EQ
Market Capital 64654812.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.neuralstem.com
CUR Address
CUR
9700 Great Seneca Highway
Rockville, MD 20850
United States
Phone: 301-366-4841
CUR Latest News
Interactive Technical Analysis Chart Neuralstem, Inc. ( CUR AMEX USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Neuralstem, Inc.
CUR Business Profile
Neuralstem, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatments for central nervous system disease based on human neural stem cells and the use of small molecule compounds. The company’s stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its clinical program products include NSI–566, which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, and Phase I clinical trials for chronic spinal cord injury. The company’s clinical development products also comprise NSI–566 that is in Phase I/II clinical trials for motor deficits due to ischemic stroke in China; and NSI–189 that is in Phase Ib for the treatment of major depressive disorders. Neuralstem, Inc. was founded in 1996 and is headquartered in Rockville, Maryland.